Eight healthy volunteers received single doses of either mianserin 10 mg, mianserin 20 mg, amitriptyline 25 mg or placebo. Critical flicker frequency, reaction time, digit substitution and addition times were tested up to six hours afterwards. Mianserin 20 mg and amitriptyline 25 mg significantly prolonged reaction time and mianserin 10 mg and 20 mg significantly reduced critical flicker frequency. No other significant effects were found. Patients should be warned of possible sedation when first starting treatment with mianserin.
Get full access to this article
View all access options for this article.
References
1.
CoppenAGuptaRMontgomerySGhoseKBaileyJBurnsBde RidderJ J (1976) Mianserin hydrochloride: a novel antidepressant. British Journal of Psychiatry129, 342.
2.
CromePNewmanB (1977) Poisoning with maprotiline and mianserin. British Medical Journal2, 260.
3.
FellP JQuantockD Cvan der BurgW J (1973) The human pharmacology of GB94 – a new psychotropic agent. European Journal of Clinical Pharmacology5, 166.
4.
GhoseK (1976) Correlation of pupil reactivity to tyramine or hydroxyamphetamine and tyramine pressor responses in patients treated with amitriptyline or mianserin. British Journal of Clinical Pharmacology3, 666.
5.
GhoseKCoppenATurnerP (1976) Autonomic actions and interactions of mianserin hydrochloride (Org. GB94) and amitriptyline in patients with depressive illness. Psychopharmacology49, 201.
6.
MurphyJ E (1975) A comparative clinical trial of ORG GB 94 and imipramine in the treatment of depression in general practice. The Journal of International Medical Research3, 251.
7.
OgleC WTurnerP (1974) The effects of oral doses of oxprenolol and of propranolol on CNS function in man. Journal of Clinical Pharmacology1, 256.
8.
SeppalaT (1977) Psychomotor skills during acute and two-week treatment with mianserin (ORG GB94) and amitriptyline and their combined effects with alcohol. Annals of Clinical Research9, 66.
9.
WheatleyD (1975) Controlled trial of a new antidepressant (ORG GB94) of novel chemical formulation. Current Therapeutic Research18, 849.